Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of South Carolina
This eight-week study aims to assess the effectiveness and tolerability of escitalopram in improving symptoms of Major Depression in patients with Amyotrophic Lateral Sclerosis (ALS) or Multiple Sclerosis (MS) as measured by the HAM-D. In addition, the study will assess improvement in the quality of life in patients with Major Depression and ALS or MS.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients between 18 and 70 years of age with documented ALS or MS,
DSM-IV episode of non-psychotic Major Depression,
≥14 score on the 17-item HAM-D,
Ability to give informed consent.
You may not be if
History of psychotic disorders,
Psychotic depression,
Bipolar depression,
Suicide risk,
History of substance abuse in the previous 6 months,
History of unstable medical disorders,
Pregnancy or planning for pregnancy,
Severity of ALS or MS that limits participating in the study protocol.
Clareo Health | Escitalopram (Lexapro) for Depression MS or ALS
